67 search results for: symposium

ADVENT at EAACI 2025
Congress
13
June
2025
Congress
ADVENT at EAACI 2025

Join Profs. Brian Lipworth, Zuzana Diamant, and Philippe Gevaert at an sponsored symposium about the latest strategies for the management of co-existing type 2 asthma and severe and/or uncontrolled CRSwNP.

Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
Dermatology
Decoding Chronic Itch and More in PN: Implications of Real-World Data for Clinical Practice
expert video

This symposium highlights type 2 inflammation as a key driver of chronic itch and the characteristic skin lesions of prurigo nodularis and evaluates the real-world implications of targeted therapies on clinical practice.

View more
.
Congress
9
March
2024
Congress
The Benefits of Early Intervention in AD: More Than Skin Deep

Many AD treatment goals focus on clinical manifestations, so that if a patient is free of lesions, their disease is considered well controlled. However, the inflammatory process underlying AD reaches far beyond the skin, affecting patients in unique ways at different stages of their lives. Education on the importance of treating AD beyond the skin and altering the treatment approach to fit the individual patient will help improve clinical management and reduce long-term patient burden.

ADVENT at NAPNAP 2025
Congress
12
March
2025
Congress
ADVENT at NAPNAP 2025

Join experts Jonathan Spergel, MD, PhD, Wanda Phipatanakul, MD, MS, and Jerry Ellen Schonfeld, CPNP, at an educational symposium as they investigate the role of type 2 inflammation in pediatric diseases. The speakers will also discuss the difficulties in diagnosis and burdens patients and their families face.

Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
Dermatology
Cracking the Code: Diagnosing and Managing Skin Diseases With Type 2 Inflammation
expert video

This symposium delves into the pivotal role of type 2 inflammation in diverse skin conditions, including atopic dermatitis, prurigo nodularis, chronic spontaneous urticaria, and bullous pemphigoid. It highlights both shared and distinct disease mechanisms and patient burdens, providing crucial insights for optimizing clinical management strategies through a series of engaging panel discussions with Drs Eichenfield, Elmariah, Culton, and Hawkes.

View more
GUF PNG
Congress
4
December
2024
Congress
Translating the Science of CSU: From Pathogenesis to Patient Outcomes

Join Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau as they discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, treatment challenges, and emerging therapies.

GUF PNG
On Demand
Translating the Science of CSU: From Pathogenesis to Patient Outcomes

Watch as Drs. Michihiro Hide, Marta Ferrrer, and Ana M. Giménez-Arnau discuss chronic spontaneous urticaria (CSU) and highlight the unmet needs, importance of disease control, and emerging therapies.

ADVENT at ERS 2024
Congress
7
September
2024
Congress
ADVENT at ERS 2024

The ADVENT program will present four symposia sharing the latest science in asthma and COPD at the 2024 European Respiratory Society (ERS) Congress. Visit Booth #A4.02 to learn more about ADVENT.

ADVENT at EADV 2024
Congress
25
September
2024
Congress
ADVENT at EADV 2024

Join ADVENT at EADV 2024 congress (European Academy of Dermatology and Venereology) for 2 educational symposia on type 2 inflammation in atopic dermatitis and bullous pemphigoid. Visit Booth #A13 to learn more about type 2 inflammatory skin diseases with ADVENT.

 

UEG 2026 Symposium Thumbnail
Congress
17
October
2026
Congress
ADVENT at UEG Week 2026

Sit down with three leading experts—Professors David Rubin, MD; Evan Dellon, MD, MPH; and Thomas Greuter, MD—for a patient case–based roundtable discussion bringing together inflammatory bowel disease (IBD) and eosinophilic esophagitis (EoE) perspectives on progression and esophageal remodeling in EoE.

How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis
On Demand
How Biologic Therapy May Lead to Disease Modification in Infants and Children with Atopic Dermatitis

The underlying pathophysiology of atopic dermatitis (AD) is driven by dysregulation of type 2 immunity that contributes to skin barrier dysfunction. AD typically develops very early in life and children with AD often develop other atopic conditions such as food allergy, asthma, and allergic rhinitis in a progression called the atopic march. Early treatment may help reduce the atopic march and other comorbidities to lessen the lifetime burden created by these diseases. There may even be a window of opportunity for disease modification.